Navigation Links
FDA Approves Novel Melanoma Drug
Date:8/17/2011

WEDNESDAY, Aug. 17 (HealthDay News) -- The U.S. Food and Drug Administration on Wednesday gave its approval to Zelboraf (vemurafenib), a first-of-its-kind drug for the treatment of an often lethal form of melanoma.

The drug targets a gene mutation that's present in about half of melanomas, the deadliest form of skin cancer.

"Zelboraf is a huge step forward in the fight against metastatic melanoma and the advancement of treatment for the deadliest form of skin cancer," Dr. Anna Pavlick, director of the NYU Melanoma Program at the NYU Cancer Institute, New York City, said in a university statement. She took part in phase II and III trials of the drug and is an advisor to Zelboraf's maker, Genentech.

"The approval of Zelboraf will make a significant impact on the survival and outcomes of advanced melanoma patients," Pavlick added. "Patients taking the drug Zelboraf were 63 percent less likely to die from advanced melanoma than patients given standard chemotherapy alone," she noted.

Another expert agreed that Zelboraf may be a potent weapon against melanoma for some patients.

The drug's approval "represents a breakthrough accomplishment in targeting a therapy to a specific group of patients who can benefit," Wendy K.D. Selig, president and chief executive officer of the Washington, D.C.-based Melanoma Research Alliance, said in a statement.

The FDA approval is specifically for patients with melanoma tumors that express a gene mutation called BRAF V600E.

BRAF typically helps regulate cell growth, but the variant of BRAF targeted by Zelboraf "is the abnormal gene mutation that allows melanoma cancer cells to spread," Pavlick explained. "Since almost 50 percent of all melanoma tumors have the BRAF genetic mutation, this targeted drug therapy can be of great benefit to many patients."

Along with the drug, the FDA also approved a companion test (made by Roche Molecular Systems) that will help
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. FDA Approves Blood Thinner Brilinta for Heart Patients
2. FDA Approves Test That Spots Aggressive Breast Cancer
3. FDA Approves Test That Spots HER2-Positive Breast Cancers
4. FDA Approves Another New Drug to Fight Hepatitis C
5. FDA approves new drug for advanced melanoma
6. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
7. FDA Approves 1st New Lupus Drug in More Than 50 Years
8. FDA Approves First 3D Mammogram Device
9. FDA Approves First Pacemaker Deemed Safe During MRIs
10. FDA Approves First Drug to Prevent Premature Births
11. Swiss agency approves clinical trial of UCI-created neural stem cell therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves Novel Melanoma Drug
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... to find a colored ribbon representing a disease. A pink ... color ribbon does one think of with lung cancer?, Although ... suffering from the disease, black may be the only one ... lung cancer patients, primarily smokers between the ages of 51 ... stigma often felt by these patients, the emotional toll it ...
(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...
(Date:4/17/2014)... adrenaline after they suffer a cardiac arrest outside of ... long-term, according to new research conducted at St. Michael,s ... a cardiac arrest get adrenaline, which has been the ... Dr. Steve Lin, an emergency physician and trauma team ... treatment, long-term survival rates of patients who suffer a ...
Breaking Medicine News(10 mins):Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... , , , ... Association (AVMA) is unveiling a new online pre s ... the tools and resources available to journalists. , , The ... and often controversial issues in veterinary medicine as easy as possible for journalists ...
... VOORHEES, N.J., Aug. 13 The rates and severity ... by several factors, including antimicrobial use, other drug-prescribing factors, infection ... C. difficile that is more resistant to fluoroquinolones ... is crucial for healthcare professionals to be aware of these ...
... , MUMBAI, India, Aug. 13 Sun ... PHARMA, BSE: 524715) today announced that as of 11:59 p.m. ... (HSR) Act waiting period, previously granted by the U.S. Federal ... Department of Justice for the Tender Offer by Alkaloida Chemical ...
... KIBBUTZ SHAMIR, Israel, Aug. 13 Shamir Optical Industry Ltd. ... of innovative products and technology to the ophthalmic lens market, today ... 2009. , , For the quarter ended June ... million for the same period in 2008. The decrease in revenues ...
... health have found that its impact varies dramatically with age. ... bone strength in young people, it may protect against osteoporosis, ... team at the University of Edinburgh has shown that a ... by cannabis called the type 1 cannabinoid receptor (CB1) ...
... 2009: Research at the University of Liverpool has found ... dictate the physical state of superstructures. The ... distinguishable by their inability to be superimposed onto their ... just one mirror form of amino acids and DNA, ...
Cached Medicine News:Health News:AVMA Unveils Improved Online Press Room to Help Journalists 2Health News:AVMA Unveils Improved Online Press Room to Help Journalists 3Health News:Clostridium difficile Infection: Tracking a Virulent Pathogen 2Health News:Sun Pharmaceutical to File HSR Application for Taro Tender Offer 2Health News:Sun Pharmaceutical to File HSR Application for Taro Tender Offer 3Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 2Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 3Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 4Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 5Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 6Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 7Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 8Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 9Health News:Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results 10Health News:Molecules wrestle for supremacy in creation of superstructures 2
(Date:1/15/2014)... novel wearable injector slightly larger than an Oreo cookie may ... prescription drugs in the large doses required to treat a ... and genetic disorders.  An emerging biologic drugs ... to analysts.   Many of these drugs will require a new ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
(Date:1/14/2014)... Jan. 14, 2014   Oligomerix, Inc. , a privately held ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced today ... Valhalla, NY as of January 15, 2014 ... New York Medical College. Oligomerix, which is ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Feb. 28, 2012 Landauer, Inc. (NYSE: LDR) ... quarterly cash dividend of $0.55 per share for the second ... 3, 2012, to shareholders of record on March 9, 2012. ... global provider of technical and analytical services to determine occupational ...
... N.C., Feb. 28, 2012  In an effort to maximize ... and biotech market research leaders must constantly evaluate the ... executives need to understand the optimal balance of external ... productivity in the quickly changing healthcare industry. ...
Cached Medicine Technology:Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: